Highlights Arbutus Biopharma Corporation

Equities

ABUS

CA03879J1003

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
2.98 ^USD	+3.11%		+3.47%	+19.20%

May. 17	Sector Update: Health Care Stocks Mixed Late Afternoon	MT
May. 17	Sector Update: Health Care Stocks Softer Friday Afternoon	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Mixed Late Afternoon	May. 17	MT
Sector Update: Health Care Stocks Softer Friday Afternoon	May. 17	MT
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program	May. 17	MT
Investor Whitefort urges Arbutus Biopharma to halt stock sales, find partner	May. 17	RE
Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q1 Revenue $1.5M	May. 02	MT
Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q1 Revenue $1.5M, vs. Street Est of $3.7M	May. 02	MT
Arbutus Biopharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	Apr. 05	MT
Moderna Suffers Setback in Lawsuit by Arbutus	Apr. 04	MT
Moderna shares fall after judge sides with Arbutus in patent fight	Apr. 03	RE
Arbutus Biopharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Arbutus Biopharma, Inc. Announces Clinical Development Milestones to Advance Its HBV Pipeline	Jan. 08	CI
Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD	Nov. 09	CI
Arbutus Biopharma Posts Q3 Net Loss, Lower Revenue; CEO to Retire, 24% Research Staff Cut	Nov. 07	MT
Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q3 Revenue $4.7M, vs. Street Est of $4.7M	Nov. 07	MT
Arbutus Biopharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Arbutus Biopharma Discontinues Coronavirus, Oral RNA Destabilizer Programs, Focuses on Hepatitis B Virus Treatment Assets	23-09-11	MT
Arbutus Biopharma Corporation Announces Pipeline Updates and Dosing of First Subject in Phase 1a/1b Clinical Trial with AB-101	23-09-11	CI
Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Reports Q2 Revenue $4.7M, vs. Street Est of $6.2M	23-08-03	MT
Arbutus Biopharma Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Arbutus Biopharma Corporation

Equities

ABUS

CA03879J1003

Highlights

Filters